Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
9.28
-1.73 (-15.76%)
Jun 10, 2026, 9:43 AM EDT - Market open
Eloxx Pharmaceuticals Employees
Eloxx Pharmaceuticals had 10 employees as of December 31, 2025. The number of employees decreased by 8 or -44.44% compared to the previous year.
Employees
10
Change (1Y)
-8
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$804,000
Market Cap
31.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -8 | -44.44% |
| Dec 31, 2022 | 18 | -10 | -35.71% |
| Dec 31, 2021 | 28 | 3 | 12.00% |
| Dec 31, 2020 | 25 | -4 | -13.79% |
| Dec 31, 2019 | 29 | 0 | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Plus Therapeutics | 28 |
| ABVC BioPharma | 19 |
| RenovoRx | 17 |
| Atossa Therapeutics | 16 |
| Nutriband | 13 |
| Genenta Science | 9 |
| Hyperion DeFi | 9 |
ELOX News
- 1 day ago - Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - PRNewsWire
- 2 years ago - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases - Business Wire
- 2 years ago - Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire